IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Geoffrey W. Krissansen

6/14/2000

Title: CANCER THERAPY

Appl. No .: 10/014.887

International Filing Date:

371(c) Date: 12/11/01

Examiner: Lei Yao

Art Unit: 1642

Confirmation 2382

Number:

CERTIFICATE OF ELECTRONIC FILING I hereby certify that this paper is being electronically filled with the United States Patent and Trademark Office, Alexandria, Virginia on the date below Cindy Murphy

TRANSMITTAL

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Transmitted herewith:

- [X] Power of Attorney (2 pgs.).
- [X] Statement Under 37 CFR 3.73(b) (1 pg.).
- Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

FOLEY & LARDNER LLP

Customer Number: 38706 Telephone: (650) 251-1129

Facsimile: (650) 856-3710 Antoinette F. Konski Attorney for Applicant

Registration No. 34,202

Atty. Dkt. No. 093397-0401

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Geoffrey W. Krissansen

Title: CANCER THERAPY

1642

10/014,887 Appl. No.:

International 6/14/2000

Filing Date:

371(c) Date: 12/11/2001

Examiner: Lei Yao

Confirmation 2382

Art Unit: Number:

REVOCATION OF PRIOR POWERS OF ATTORNEY BY ASSIGNEE APPOINTMENT OF NEW POWER OF ATTORNEY BY ASSIGNEE CHANGE OF CORRESPONDENCE ADDRESS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

CANCER RESEARCH TECHNOLOGY LIMITED is the assignce of Application No. 10/014,887 filed December 11, 2001, and all continuing applications thereof, as evidenced by an Assignment recorded in the U.S. Patent and Trademark Office on March 11, 2003 at rcel/frame 013825/0819.

CANCER RESEARCH TECHNOLOGY LIMITED, through its duly-delegated representative, hereby revokes all prior Powers of Attorney submitted in this application, and

Atty. Dkt. No. 093397-0401

hereby appoints the registered patent attorneys and patent agents associated with Customer Number:

38706

as its principal attorneys to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, to transact all business in the United States Patent and Trademark Office connected therewith, and to have full power of substitution, association, and revocation, including the power to revoke the power of attorney of any associate attorney.

Please direct all future correspondence concerning this application to:

FOLEY & LARDNER LLP Customer Number: 38706

Telephone: (650) 251-1103 Facsimile: (650) 856-3710

Executed this 17 day of JULY . 2008

Bv:

CANCER RESEARCH TECHNOLOGY LIMITED

(Signature)

Keith Blundy PhD MBA

(Title)

-TCISISNE (IC-42) Approved for use through 07/31/206. (Mode 655-403) U.S. Patent and Trademark (Micc) U.S. DEPARTMENT OF COMMERCE Under the Paponeois. Reduction Act of 1995, no persons are required to respond to a collection of Homogeneois was valid and to act in carbon.

STATEMENT UNDER 37 CFR 3.73(b)		
Applicant/Patent Owner:	Geoffrey W. Krissansen	
Application No.:	10/014,887	Fited: 6/14/2000
Patent No.:		issue Date:
Docket Number:	093397-0401	
Entitled:	CANCER THERAPY	
CANCER RESEARCH TECHNOLOGY LIMITED		Corporation
(Name of Assignee)		(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is:		
 the assignee of the entire right, title, and interest; or 		
 an assignee of less than the enfire right, litle, and interest The extent (by percentage) of its ownership interest is % 		
in the patent application/patent identified above by virtue of either:		
A. An assignment from the Inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel/Frame 013825/0819 or for which a copy thereof is attached.		
OR		
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:		
 From: Krissansen, Geoffrey W.; Kanwar, Jagar Rakesh, Ching, Lal-Ming, To: Cancer, Research Ventures Limited The document was recorded in the United States Patent and Trademark Office at Resi 0/1889. Frame _0.388 Recorded _09/10/2002. 		
 From <u>Cancer Research Ventures Limited</u> <u>To: Cancer Research Technology Limited</u> The document was recorded in the United States Patient and Trade mark Office at Real <u>(1983)</u>. From <u>6.019</u>, Recorded <u>2011/2003</u> 		
3. From:	To:	
The document was rocorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.		
Additional documents in the chain of title are listed on a supplemental sheet.		
Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., a true copy of the original document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO, See MPEP 302.08;		
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.		
Keith Blundy F	HD MBA	Date
Chief Executiv	e Officer	Telephone Number
OHIGHEROOUT	ped wistness.	+442072693640
THE		

This collection of information is required by \$7 CFR 3.75(b). The information is required to obtain or retain a benefit by the public which is to fire (and by the USPTC to process) is expirated by \$2 CFR 3.75(b). The information is required to obtain or retain a benefit by the public which is to reper in the process of the public which is to reper in the process of the public which is to retain a public which is the public